Study of Coronavirus Disease (COVID-19) Outbreak in India

Study of Coronavirus Disease (COVID-19) Outbreak in India

The Open Nursing Journal 22 Mar 2021 REVIEW ARTICLE DOI: 10.2174/1874434602115010062



COVID-19 is an infectious disease caused by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). It has been recognized as a pandemic by the World Health Organization (WHO) on 11th March, 2020.


To identify various factors that can increase coronavirus spread in India and predict COVID-19 cases up to 27th December, 2020, minimum and maximum number of deaths due to COVID-19 in India.


This work predicts COVID-19 cases, the minimum and the maximum number of deaths due to COVID-19 in India based on the infection rate and suspected cases.


Our result shows that the number of COVID-19 cases will increase exponentially in India to approximately 859421415 cases by 27th December 2020.


The spread of COVID-19 in India depends on a lot of factors such as religious congregation, social contact structure, low testing rates, identification of COVID-19 suspects, measures such as lockdown and sealing of hot stop, etc. taken by the Indian government. In India, lockdown proved to be a good decision.

Keywords: Prediction, Coronavirus, COVID-19, Tablighi Jammat, Pandemic, Outbreak, Disease, SARS-CoV-2.


The outbreak of novel pathogenic Coronavirus (2019-nCoV) [1-6] was first identified in Wuhan city of Hubei Province of South China on 31st December, 2019. It was recognized as a Pandemic by the World Health Organization on 11th March, 2020. The Coronavirus disease has been officially named as COVID-19. COVID-19 is an infectious disease caused by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). World Health Organization (WHO) had declared the outbreak a Public Health Emergency of International Concern on 30th January, 2020. There are several reports regarding the timeline of the Coronavirus outbreak. According to media reports on unpublished Chinese government data, the first case of COVID-19 emerged on 17th November, 2019 [7-10]. According to a study by Chinese researchers published in the Lancet medical journal, the first patient with the symptoms of COVID-19 was identified on 1st December, 2019 [11-15]. Like Middle East Respiratory Syndrome (MERS-CoV) [16-20] and Severe Acute Respiratory Syndrome (SARS-CoV) [21-24]. Coronavirus is a large family of viruses that causes illness ranging from the common cold to severe disease. COVID-19 is a disease that mainly affects the respiratory system and most infected people recover without requiring specific treatment. People above the age of 60 years and who have underlying medical conditions are at higher risk. According to World Health Organization (WHO), the symptoms of COVID-19 include:

  • Fever, tiredness, dry cough as the most common symptoms.
  • Sore throat, diarrhoea, pains and aches, conjunctivitis, loss of taste or smell, headache, discolouration of toes or fingers or rashes on skin as less common symptoms.
  • Shortness of breath or difficulty breathing, loss of movement or speech, chest pain as some serious symptoms.

The Coronavirus disease first emerged in China in December 2019 and spread globally rapidly. When a person with COVID-19 [5-8] exhales or coughs, small droplets spread out in the surrounding environment and land on surfaces and objects around the person. Other people then catch COVID-19 directly by inhaling these small droplets or indirectly by touching contaminated surfaces or objects then touching their nose, mouth or eyes. The survival of Coronavirus depends on various factors such as humidity or temperature of the environment and type of surface. The risk of catching COVID-19 from the faeces of an infected person and someone with no symptoms at all appears to be very low. In India, the first case of coronavirus was reported in Kerala on 30th January, 2020 [25]. As of 5th December, 2020, the recovery rate of COVID-19 in India is 98.48%, a total of 9499710 cases and 140216 deaths have been confirmed by worldometer website in India. The number of infections could be a substantial underestimate due to low testing rates of India [26, 27]. Following are some protective measures against COVID-19, advised by the World Health Organization (WHO) [28].

(1) Maintain social distancing: you should maintain at least 1-meter distance from a person who is sneezing or coughing.

(2) Regular hand washing: one should thoroughly and regularly clean his/her hands with soap and water or alcohol-based hand wash.

(3) Seek medical care early, if you have cough, fever and shortness of breath.

(4) Avoid unnecessary travel

(5) Maintain respiratory hygiene: you should not sneeze in the bare hand, always make sure that you cover your nose and mouth with a tissue or with your bent elbow.

(6) Avoid touching nose, mouth and eyes: if you touch your eyes, mouth and nose with contaminated hands, then the virus can enter your body.

On 28th March 2020, there were 25,778 numbers of government hospitals and 7.13 lakh number of beds in government hospitals and in government hospitals, the availability of beds was 0.55 beds per 1000 population [28]. Therefore, India had taken several measures to stop coronavirus spread. Such measures are as follows:

(1) Lockdown the entire nation for 21 days from 24th March 2020 to 14th April 2020 to break Coronavirus chain.

(2) India is trying to quickly ramp up its fragile healthcare facilities.

(3) Conversion of railway coaches and medical colleges into isolation wards, etc.

In this study, we tried to present an early prediction of the epidemic of COVID- 19 in India based on infection rate and suspected cases and our mathematical model forecasts the minimum and the maximum number of deaths, due to COVID-19 in India, for the different number of infected cases. Our results are supposed to provide important information regarding the upcoming infected number of people, which will help manage COVID-19 crisis.

The contribution of this paper is structured as follows: Section 2 elaborates motivation for research. Section 3 depicts the methodology and section 4 discusses the result of the proposed model and section 5 concludes the research paper by summarizing our work.


The outbreak of Coronavirus has brought life to a near standstill in almost every part of the world. The cases of COVID-19 have been increasing day by day. As of 6th December 2020, a total of 66,964,380 infected patients and 1,536,618 deaths have been confirmed by the Worldometer website in the world. The highest number of deaths have been recorded in United States so far. According to the World Health Organization (WHO), the most urgent threat to the ability to save lives is a chronic shortage of protective equipment. As of 6th December, 2020, the United States has recorded the highest number of Coronavirus cases i.e. 14,983,425 and 287,825 deaths (Table 1). [29]

Table 1.
Total number of COVID cases.
Countries Total Cases Total Deaths Total Recovered
Italy 1,709,991 59,514 896,308
USA 14,983,425 287825 8,787,738
Spain 1,699,145 46,252 150376
China 86,619 4,634 81,706
Iran 1,040,547 50,310 730,798
India 9,644,529 140,216 9,100,792

Table 2 shows that the total number of cases (COVID-19), deaths due to coronavirus and recoveries of patients infected with COVID-19 for different countries, as of 6th December, 2020. There are many companies and academic institutions racing to find a COVID-19 cure. Lopinitor, ritonavir, ribavarin, darunavir and remindasvir are some drugs that are under trials for COVID-19 treatment. Many COVID-19 vaccine projects are using the approaches which have already been tested and tried while others are using new technologies. The vaccine must be tested to ensure that they will not cause any side effects. The trial methodology of a vaccine lasts between six and eight months. If the vaccine is prepared, then the biggest challenge would be its production in the volume necessary to end a pandemic. Following are some COVID-19 vaccine candidates currently in Phase 3 trial

Table 2.
Number of infected and death cases in india.
Date Infected Cases Deaths Death Rate (%) Country
1 to 30 April 34863 1154 3.310 India
1 to 31 May 190609 5408 2.837 India
1 to 30 June 585792 17410 2.972 India
1 to 31 July 1697054 36551 2.153 India
1 to 31 August 3687939 65435 1.774 India
1 to 30 September 6310267 98708 1.564 India
1 to 31 October 8182881 122149 1.492 India
1 to 30 November 9463254 137659 1.454 India
1 to 30 April 236356 25437 10.76 Spain
1 to 31 May 249679 29050 11.63 Spain
1 to 30 June 259119 29385 11.34 Spain
1 to 31 July 311358 29476 9.466 Spain
1 to 31 August 515980 30148 5.842 Spain
1 to 30 September 815543 32942 4.039 Spain
1 to 31 October 1303411 37311 2.862 Spain
1 to 30 November 1671548 45069 2.696 Spain
1 to 30 April 205449 28036 13.64 Italy
1 to 31 May 233000 33508 14.38 Italy
1 to 30 June 240599 34921 14.51 Italy
1 to 31 July 247537 35295 14.25 Italy
1 to 31 August 269217 35483 13.18 Italy
1 to 30 September 314861 35894 11.39 Italy
1 to 31 October 679428 38618 5.683 Italy
1 to 30 November 1601551 55576 3.470 Italy
1 to 30 April 82862 4633 5.591 China
1 to 31 May 83001 4634 5.583 China
1 to 30 June 83531 4634 5.547 China
1 to 31 July 84292 4634 5.497 China
1 to 31 August 85048 4634 5.448 China
1 to 30 September 85403 4634 5.426 China
1 to 31 October 85973 4634 5.390 China
1 to 30 November 86530 4634 5.355 China
1 to 30 April 163009 6623 4.062 Germany
1 to 31 May 183494 8605 4.689 Germany
1 to 30 June 195832 9052 4.622 Germany
1 to 31 July 210665 9224 4.378 Germany
1 to 31 August 244792 9371 3.828 Germany
1 to 30 September 292911 9571 3.267 Germany
1 to 31 October 531790 10583 1.990 Germany
1 to 30 November 1069763 16862 1.576 Germany

(1) BNT162:

• It is a mRNA-based vaccine

•It has been jointly developed by Pfizer and BioNtech

(2) AZD1222:

• It is a replication-deficient viral vector vaccine, a chimpanzee adenovirus vaccine.

• It has been developed by AstraZeneca and University of Oxford

(3) mRNA-1273:

• It is also an mRNA- based vaccine.

• Based on prior studies of related coronaviruses like those that cause Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), Moderna has developed this vaccine.

(4) Covaxin:

• It is an inactivated vaccine or killed vaccine.

• It has been developed by Bharat Biotech and National Institute of Virology of India.

(5) JNJ-78436735, formerly called Ad26.COV2.S

• It is a Non-replicating vector vaccines

• Using AdVac and PER.C6 systems, Johnson & Johnson has developed this vaccine.

(6) Ad5-nCoV:

• It incorporates the adenovirus type 5 vector (Ad5)

• It has been developed by China’s CanSino Biologics

(7) CoronaVac:

• It is a formalin-inactivated and alum-adjuvanted candidate vaccine.

• It has been developed by Chinese biopharmaceutical company Sinovac.

But still, we are not sure that when we will get a workable vaccine against COVID-19. So, it has become very important for us to reduce the risk of infection by following the guidelines given by the World Health Organization (WHO). In this note, we will see the economic impact of COVID-19.

Several countries have been adversely impacted due to the spread of COVID- 19 globally. According to a report from the consultancy McKinsey and Company, the United States could take three years to recover from the impact of COVID-19 crisis. On 26th March, 2020, Moody’s Investors Service revised its estimate for India’s GDP growth in the financial year 2020 to 2.5% from 5.3% and CRISIL (rating agency of India) slashes its projection for India's GDP growth in the financial year 2021 from 5.7% to 5.2%. Isolation is important as it acts as a defence against the spread of COVID-19 virus. This study would help to understand which control measures work. The people with an illness must be identified first to prevent further transmission of the virus. There are many uncertainties regarding COVID-19. Therefore, research must be conducted to find out the answers to various questions like by which month coronavirus will fade out, number of deaths, infection rate, etc., which will help the government in taking the rights measures, benefit various health organizations and the community at large. Good research in this area can save many lives and will also be helpful for other researchers working in the same field. An accurate prediction about the spread of COVID-19 in the next few weeks could be used to make better business decisions.

Table 3 shows the total number of infected cases, number of deaths and death rate for six countries, viz., Italy, Germany, Spain, China and India.


In Fig. (1), X-axis represents the number of weeks i.e. week 1 from 22nd March to 29th March, week 2 from 30th March to 5th April, week 3 from 6th April to 12th April, etc. Y-axis shows the number of infected cases and deaths due to Coronavirus in India. The graph shows that the number of deaths was very less in the first week i.e. 27 deaths for 1024 cases in India, which increased to 140216 deaths in the week from 20th November to 5th December amid lockdown.

In Fig. (2), X-axis shows the number of weeks i.e. week 1 from 22nd March to 29th March, week 2 from 30th March to 5th April, week 3 from 6th April to 12th April, so on. Y-axis shows the number of infected cases and deaths due to Coronavirus in Italy.

Table 3.
Number of infected and death cases in India.
Cases Death Rate (%) Predicted No. of Deaths
Infected Cases Minimum Maximum Minimum Maximum
10,000,00 3.87 5 38700 50000
20,000,00 2.90 5 58000 100000
30,000,00 2.43 5 72900 150000
40,000,00 2.19 5 87600 160000
50,000,00 2.04 4 102000 200000
60,000,00 1.87 4 112200 240000
70,000,00 1.75 4 122500 280000
80,000,00 1.62 4 129600 320000
90,000,00 1.54 4 138600 360000
10,000,000 1.52 4 152000 400000
11,000,000 1.59 4 165000 440000
12,000,000 1.40 4 168000 480000
13,000,000 1.36 3 176800 390000
14,000,000 1.25 3 175000 420000
15,000,000 1.10 3 165000 450000
16,000,000 1 3 160000 480000
Fig. (1). Weekly Infected and Death Cases in India.
Fig. (2). Weekly Infected and Death Cases in Italy.

In Fig. (3), Y-axis represents the number of infected cases and deaths due to COVID-19 in Spain while the X-axis represents the number of weeks, week 1 from 22nd March to 29th March, week 2 from 30th March to 5th April, week 3 from 6th April to 12th April, 2020 and so on.

Fig. (3). Weekly Infected and Death Cases in Spain.

In Fig. (4), X-axis shows the number of infected cases and deaths due to COVID-19 in China while the X-axis shows the number of weeks i.e. week 1 from 22nd March to 29th March, week 2 from 30th March to 5th April, week 3 from 6th April to 12th April, 2020 and so on.

Fig. (4). Weekly Infected and Death Cases in China.

In Fig. (5), Y-axis shows the number of infected cases and deaths due to COVID-19 in Germany while the X-axis shows the number of weeks i.e. week 1 from 22nd March to 29th March, week 2 from 30th March to 5th April, week 3 from 6th April to 12th April, 2020 and so on.

Fig. (5). Weekly Infected and Death Cases in Germany.
Fig. (6). Date Wise Suspected and Infected Cases in India.
Fig. (7). Weekly Number of Deaths in Different Countries.
Fig. (8). Predicted number of Deaths for Different Number of Infected Cases in India.

In Fig. (6), Y-axis shows the number of coronavirus cases date-wise in India. The number of suspected cases are shown by blue colour line and the number of infected cases in India are shown by the mustard colour line. We propose the minimum and the maximum number of predicted deaths based on the minimum and maximum death rate, as shown in Table (4) below:

Fig. (7) shows weekly deaths in different countries, viz., China, Germany, Italy, China, Spain and India. From the result, it is evident that Italy has the highest death rate in comparison to other countries while India has the lowest death rate.

In Fig. (8), X-axis shows the number of infected cases and Y-axis shows the predicted number of deaths. The minimum number of predicted deaths is shown by blue colour line and the maximum number of predicted deaths, due to COVID-19 in India are shown by the red colour line. As shown in the graph, for 10, 000, 00 infected cases, the number of deaths would lie between 38700 and 50000, and for 20, 000, 00 infected cases, the number of deaths would lie between 58000 and 100000.

Table 4.
Descriptions of the term used during the calculation of infected cases.
Term Definition
D Date
IR Infected Rate
S Number of Suspected Cases
Y Total Infected People
n Number of Day

3.1. Issues for Prediction of COVID-19 Cases in India

3.1.1. Religious Congregation:

Over 3400 people had gathered in Delhi for Tablighi Jamaat event on 13th March 2020. Following are some cases of COVID-19, which had a relationship with this event.

  • On 26th March, after batting with COVID-19, a businessman died in Srinagar.
  • On 30th March, six deaths because of Coronavirus were reported from Telangana (India).
  • On 31st March, ten people had tested positive from Coronavirus from Andaman and Nicobar Islands of India.

Around 1,500 people were sent to their respective states from Markaz on 23rd March 2020 and it is not known that how many of them were coronavirus positive. According to the Union Health Ministry, 2,100 foreigners visited India for Tablighi event in 2020 and these were from Thailand, Malaysia, Indonesia, Nepal, Myanmar, Sri Lanka, Bangladesh and Kyrgyzstan. On 2nd April, over 5,000 of those identified who have attended the congregation have been quarantined. On 23rd March 2020, around 1,500 people were sent to their respective states from Markaz and their COVID-19 status is unknown. This gathering can make a trail of infection. Our work shows that these 1500 people can affect other 120 people or more in a single day. Based on the hypothesis, we can say that at least 30 people may have coronavirus symptoms, which further infect four other people during their journey from their home to Nizamuddin Markaz and from Markaz to their home. The Indian government announced 21-days complete lockdown on 23rd March. The lockdown started from 24th March and ended on 3rd May. As of 6th April 2020, nearly a third of total COVID-19 positive cases were linked to the Tablighi Jammat congregation. Before the Jammat event, the rate of doubling of COVID-19 cases in India was 7.4 days, which accelerated to 4.1 days after the event. More than 8,000 people attended the congregation in early March, according to the Indian government. India has tested 0.10 samples per thousand people as of 9th April 2020, which is not enough to identify the attendance of Jammat event. Any such event in the future will be detrimental to the well-being of the nation and will severely affect the health of people.

3.1.2. Lifting of the Lockdown:

Completely lifting the lockdown can speed up the infection rate. Considering the fact that lockdown was removed by 14th April 2020, a person having COVID-19 could infect other 406 people within a month, while during lockdown, a person having COVID-19 was infecting approx 2.5 people within a month. Several State governments in India declared the sealing of coronavirus hotspot to control COVID- 19. If implemented effectively, the measures will prove to be helpful in controlling further coronavirus spread. We strongly recommend further lockdown extension. The lockdown will not be enough to stop coronavirus spread; it is just a response time in which some important measures such as contact tracing, social distancing and isolating those in close contact with infected patients etc, can be taken. India has been on lockdown from 24th March to 14th April but it should be extended to get enough time to cope up with the intensifying situation.

3.1.3. Congested Dwellings in India:

Some places like Dharavi slum of Mumbai and congested dwellings such as Sangli in Maharashtra could increase the risk of community transmission.

3.1.4. The Testing Rate in India:

Testing rate of COVID-19 in India is one of the lowest testing rates in the world. The people who have travelled to high-risk countries or those who have been in touch with a person or symptomatic healthcare worker or patients with severe respiratory disease are eligible for testing. According to the Indian Council of Medical Research, 25,254 samples have been tested in India as of 25th March, out of which 581 were positive. The current number of infected cases is small for a country like India. One of the reasons for this may be inadequate testing. Lockdown will not be enough to break the infection chain; COVID-19 cases in India have been increasing amid lockdown. India has a lower percentage of positive cases as it has a lower test rate. India may see a surge in cases in the upcoming days as it is increasing its testing rates. As of 25th March 2020, about one in every test conducted for COVID-19 in India were positive. In comparison, about a sixth in Austria, about a quarter in Italy were positive. The number of COVID-19 infections is increasing as the Indian government has allowed private labs to conduct tests. According to the Indian Council of Medical Research, India has tested 47,951 samples by 31st March. According to the Indian Council of Medical Research chief Epidemiologist RR Gangakhadkhar, India has a testing capacity of 12,000 samples a day. Our model suggests that India needs to test more as more tests will identify more coronavirus patients. Some of the Countries such as South Korea and Germany have managed to control fatalities from COVID-19 to a large extent as they conducted large scale testing.

3.2. Prediction for COVID-19 Infected Cases in India

Fig. (9) consists of two horizontal timelines, the first horizontal timeline shows date wise suspected cases while the second horizontal timeline shows the weekly infected rate in India.

Fig. (9). Relation between Date Wise Suspected and Infected Cases in India.

Description of notation used is depicted in Table 5. [30, 31] We propose a simple mathematical model for the calculation of weekly infected cases. Description of such a model is given below:

Table 5.
Forecasting of COVID-19 cases for india.
Weeks Tests (Suspected cases) No of Confirmed Cases in India Infected Rate (%) Range
22 to 29 March 38442 1024 2.663753187 2 to 4
30 to 5 April 89534 4289 4.79035897 -
6 to 12 April 195743 9205 4.702594729 -
13 to 19 April 401586 17615 4.38635809 -
20 to 26 April 625309 27890 4.46019488 4 to 5
27 to 3 May 1046450 42505 4.061828085 -
4 to 10 May 1609037 67161 4.173987298 -
11 to 17 May 2227642 95698 4.29593265 -
18 to 24 May 2943421 138536 4.706632181 -
25 to 31 May 3737027 190609 5.100551856 -
1 to 7 June 4666386 257486 5.517889004 5 to 6
8 to 14 June 5658614 332783 5.880998421 -
15 to 21 June 6807226 426910 6.271423925 6 to 7
22 to 28 June 8227802 549197 6.674893246 -
29 to 5 July 9789066 697836 7.128729135 7 to 8
6 to 12 July 11587153 879466 7.590009384 -
13 to 19 July 13791869 1118107 8.107001306 8 to 9
20 to 26 July 16291331 1436019 8.814620487 -
27 to 2 August 19821831 1804702 9.104618035 -
3 to 9 August 24106535 2214137 9.184799889 9 to 8
10 to 16 August 29309703 2647316 9.032217078 -
17 to 23 August 35292220 3105185 8.798497233 -
24 to 30 August 41461636 3619169 8.7289585 8 to 9
31 to 6 Sep 48831145 4202562 8.606314679 -
7 to 13 Sep 56260928 5115893 9.093154311 9 to 8
14 to 20 Sep 63661060 5485612 8.616903331 -
21 to 27 Sep 71257836 6073348 8.523059836 -
28 to 4 Oct 78992534 6622180 8.383298604 8 to 7
5 to 11 Oct 86877242 7119300 8.194666216 -
12 to 18 Oct 94224190 7548238 8.010934347 -
19 to 25 Oct 102523469 7909050 7.714380012 -
26 to 1 Nov 109887303 8266914 7.5230839 -
2 to 8 Nov 117736791 8553864 7.265243028 7 to 6
9 to 15 Nov 124836819 8845617 7.08574367 -
16 to 22 Nov 131836819 924176101 7.01 -
23 to 29 Nov 139200653 920116316 6.61 -
30 to 6 Dec 147050141 955825916 6.5 -
7 to 13 Dec 154150169 971146064 6.3 6 to 5
14 to 20 Dec 161150169 9830160301 6.1 -
21 to 27 Dec 168514003 859421415 5.1 -
Y1= S1 ×IR1
Y2= S2 ×IR2
Y3= S3 ×IR3
Y4= S4 ×IR4
Yn= Sn ×IRn

Here, we calculate the value of the infected rate for India based on the infected rate for different countries, which is depicted in Table 4.

We predict that the number of COVID-19 cases will increase exponentially in India to approximately 859421415 cases by the end of 2020. While predicting the theoretical number of infected cases in India based on infection rate, we are considering the fact that the lockdown would be extended until the first week of May and all other parameters are constant.

Table 5 shows the number of suspected cases and infected cases, infected rate and range of infected rate. Our results show that there will be 859421415 infected cases in India in the last week of December 2020.


This paper has presented a study of the Coronavirus Disease (COVID-19) Outbreak in India. The spread of COVID-19 in India depends on a lot of factors especially, the religious gathering of people, which can act as a super spreader of COVID-19. Any such gathering in the future will be detrimental to the health of people. In India, lockdown proved to be a good decision and it should be extended further. There are many unknown parameters that can cause large uncertainties in the prediction; the prediction is supposed to help the Government in further decision making and in coping with the ongoing coronavirus transmission in India. As predicted by this study, more focus should be given to the control measures such as speeding the testing rate, maintain social distancing, avoid unnecessary gathering. If all these efforts are taken into consideration, then the severity of COVID-19 in India may be controlled at a relatively low level finally. The findings of this study increase the knowledge level of nurses, which will enhance their willingness to work with high-risk patient groups. The results of this paper will be useful in managing the healthcare resources in advance and for the development of good nursing.


V.D proposed a prediction method for COVID-19 cases in India, which is evaluated in terms of death and infection rate. V.K guided in the prediction for death and infected COVID-19 cases in India. All authors read and approved the final manuscript.


Not applicable.




The authors declare no conflict of interest, financial or otherwise.


Declared none.


Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi 2020; 41(2): 145.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine 2020.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia. N Engl J Med 2020.
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; 395(10223): 470-3.
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
Perlman S. Another decade, another coronavirus 2020.
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9.
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565-74.
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020; 94(7)e00127-20
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-13.
Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 2020; 395(10223): 514-23.
Marra MA, Jones SJ, Astell CR, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003; 300(5624): 1399-404.
Holmes KV. SARS-associated coronavirus. N Engl J Med 2003; 348(20): 1948-51.
de Groot RJ, Baker SC, Baric RS, et al. Middle east respiratory syndrome coronavirus (MERS-CoV): Announcement of the coronavirus study group. J Virol 2013; 87(14): 7790-2.
Peiris JSM, Lai ST, Poon LLM, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361(9366): 1319-25.
Snijder EJ, Bredenbeek PJ, Dobbe JC, et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 2003; 331(5): 991-1004.
Thiel V, Ivanov KA, Putics Á, et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol 2003; 84(Pt 9): 2305-15.
Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450-4.
Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1967-76.
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003; 300(5626): 1763-7.
Goyal K, Chauhan P, Chhikara K, Gupta P, Singh MP. Fear of COVID 2019: First suicidal case in India! Asian J Psychiatr 2020; 49101989
Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q 2020; 40(1): 68-76.
Key considerations for repatriation and quarantine of travellers in relation to the outbreak of novel coronavirus 2019. Available at:
Total Coronavirus Cases in India. 2020. Available at: https://www.